Proto Script Pharmaceutical (Proto Script Pharmaceutical) EBIT per Share : $-0.01 (TTM As of Sep. 2017)

View and export this data going back to 2011. Start your Free Trial

What is Proto Script Pharmaceutical EBIT per Share?

Proto Script Pharmaceutical's EBIT per Share for the three months ended in Sep. 2017 was $-0.00. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2017 was $-0.01.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Proto Script Pharmaceutical's EBIT per Share or its related term are showing as below:

PSCR's 3-Year EBIT Growth Rate is not ranked ^*
in the Business Services industry.
Industry Median: 11.3
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Proto Script Pharmaceutical's EBIT for the three months ended in Sep. 2017 was $-0.17 Mil.

Proto Script Pharmaceutical EBIT per Share Historical Data

The historical data trend for Proto Script Pharmaceutical's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Proto Script Pharmaceutical EBIT per Share Chart

Proto Script Pharmaceutical Annual Data

Trend

May12

May13

May14

May15

May16

EBIT per Share

Proto Script Pharmaceutical Quarterly Data
	Nov12	Feb13	May13	Aug13	Nov13	Feb14	May14	Aug14	Nov14	Feb15	May15	Aug15	Nov15	Feb16	May16	Sep16	Dec16	Mar17	Jun17	Sep17
EBIT per Share	Get a 7-Day Free Trial															-	-	-	-	-

Proto Script Pharmaceutical EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Proto Script Pharmaceutical's EBIT per Share for the fiscal year that ended in May. 2016 is calculated as

	EBIT per Share		(A: May. 2016 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-0.033	/	30.480
=	-0.00

Proto Script Pharmaceutical's EBIT per Share for the quarter that ended in Sep. 2017 is calculated as

	EBIT per Share		(Q: Sep. 2017 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-0.166	/	49.140
=	-0.00

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.01

Proto Script Pharmaceutical (OTCPK:PSCR) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Proto Script Pharmaceutical EBIT per Share Related Terms

Thank you for viewing the detailed overview of Proto Script Pharmaceutical's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Proto Script Pharmaceutical (Proto Script Pharmaceutical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Industrials » Business Services » Proto Script Pharmaceutical Corp (OTCPK:PSCR) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

9830 6th Street, Suite 103, Rancho Cucamonga, CA, USA, 91730

Website

http://www.psphomecare.com

Proto Script Pharmaceutical Corp is primarily in the business of repair power wheelchairs and scooters, which are classified as durable medical equipment (DME) products and reimbursable by healthcare insurance providers. It has various contracts with state and governmental insurance providers, among others. These contracts provide the company with the right to sell and repair DME and its health care insurance contracts allow it the ability to service patients nationally. The group currently has its presence of repair facilities in Las Vegas, Nevada, Rancho-Cucamonga, and Anaheim, California.

Proto Script Pharmaceutical (Proto Script Pharmaceutical) Headlines

No Headlines